A Multi-Target Phytotherapeutic Approach to Benign Prostatic Hyperplasia: Preclinical Characterization of a PhytoBPH-Mix

TL;DR

A new plant-based mixture shows promise in treating benign prostatic hyperplasia by targeting multiple causes with fewer side effects.

Contribution

The study introduces and evaluates a novel multi-component phytocomplex for BPH treatment with multi-target effects.

Findings

The mixture significantly inhibited 5α-reductase activity in vitro.

It reduced the release of pro-inflammatory cytokines IL-6 and TNF-α.

The formulation showed antibacterial effects against E. coli.

Abstract

Background: Benign prostatic hyperplasia (BPH) is a prevalent condition affecting over 50% of men aged 60 and above, often leading to lower urinary tract symptoms that significantly impact quality of life. Current pharmacological treatments, including α-adrenergic receptor antagonists and 5α-reductase inhibitors, are associated with adverse effects, prompting the exploration of alternative therapies. This study investigates the potential role of a novel multi-component phytocomplex (PhytoBPH-Mix) comprising Serenoa repens, Pygeum africanum, Urtica dioica, Epilobium angustifolium L., Protium heptaphyllum, lycopene, Vitamin E, zinc, and selenium. Methods: The anti-androgenic, anti-inflammatory, and antimicrobial properties of the mixture were evaluated in vitro. Results: The formulation significantly inhibited 5α-reductase activity, reduced the release of pro-inflammatory cytokines (IL-6 and TNF-α), and exhibited antibacterial effects against E. coli compared to individual extracts. Conclusions: These findings suggest that this specific mixture offers a promising natural alternative or an adjuvant for managing BPH by targeting multiple pathological mechanisms with minimal side effects and could also serve as an effective adjuvant in conventional therapy.

Figures